

CAMZYOS[®] REMS Program Overview

This overview describes the requirements of the CAMZYOS REMS and the responsibilities of healthcare providers, pharmacists, and patients.

What is the CAMZYOS REMS?

A **R**isk **E**valuation and **M**itigation **S**trategy (**REMS**) is a strategy to manage known or potential risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure the benefits of a drug outweigh its risks.

Because of the serious risk of heart failure due to systolic dysfunction, CAMZYOS is available only through a restricted program called the CAMZYOS REMS.

CAMZYOS may increase the risk of heart failure due to systolic dysfunction; patients may experience heart failure at any time during treatment with CAMZYOS.

What are the requirements of the CAMZYOS REMS?

In order for patients to receive CAMZYOS, healthcare providers, pharmacies, and patients must comply with the requirements of the CAMZYOS REMS.

Phone: 833-628-7367 Fax: 833-299-9539 CAMZYOSREMS.com

Program Overview

Healthcare Provider Requirements

Only healthcare providers certified in the CAMZYOS REMS are authorized to prescribe CAMZYOS.

Become Certified	Before prescribing CAMZYOS:
(One Time)	1. Review the Prescribing Information
	2. Review the following educational materials:
	Program Overview (this document)
	Education Program for Healthcare Providers and Pharmacies
	3. Successfully complete and submit the following to become certified:
	 Healthcare Provider Knowledge Assessment Healthcare Provider Enrollment Form
	4. Receive confirmation of CAMZYOS REMS certification
Enroll Patients	Before starting each patient on CAMZYOS:
	1. Counsel the patient, using the <i>Patient Brochure</i> , on the:
	 Risk of heart failure due to systolic dysfunction, including how to recognize and respond to the symptoms of heart failure due to systolic dysfunction
	 Risk of drug-drug interactions with CYP2C19 or CYP3A4 inhibitors and inducers and the need to inform healthcare providers of all the prescription and nonprescription medications they take
	2. Provide the patient with the <i>Patient Brochure</i>
	3. Assess the patient's cardiovascular status and the appropriateness of initiating treatment by obtaining an echocardiogram
	 Assess the patient's prescription and nonprescription medications and supplements for drug-drug interactions
	5. Enroll the patient by completing the <i>Patient Enrollment Form</i> together with the patient and documenting and submitting the confirmation of the echocardiogram, screening for drug-drug interactions, and authorization for treatment to the REMS
	 Healthcare providers can specify an initial treatment start date that falls within 90 days of <i>Patient Enrollment Form</i> submission. If a date is not specified, the REMS treatment start date will be based on the initial dispense shipment date of the patient's first dose of CAMZYOS. A REMS-certified healthcare provider or designee can use the REMS website to submit an updated treatment start date within 90 days of submitting the <i>Patient Enrollment Form</i>

Program Overview

Healthcare Provider Requirements (continued)

At All Times for Each Patient	Once the patient is on CAMZYOS:
	 Counsel the patient on the risk of heart failure due to systolic dysfunction and drug-drug interactions with CYP2C19 and CYP3A4 inhibitors and inducers, and the related safe-use requirements using the <i>Patient Brochure</i>
	Assess the patient's cardiovascular status, including obtaining echocardiograms at the frequency described in the Prescribing Information:
	i. 4, 8, and 12 weeks after treatment initiation, then every 3 to 6 months thereafter (depending on echocardiogram results)
	ii. 4 weeks after interruption of treatment
	iii. 4 and 12 weeks after any dose change (including restart of treatment)
	iv. 4 and 12 weeks after initiating a weak to moderate CYP2C19 inhibitor or a moderate to strong CYP3A4 inhibitor
	Assess the patient's current prescription and nonprescription medications and supplements for drug-drug interactions
	4. Complete, sign, and submit a <i>Patient Status Form</i> to the CAMZYOS REMS, documenting that the patient has been counseled, the echocardiogram for the required time interval based on the Prescribing Information has been performed, assessment of drug-drug interactions has been performed, and it is appropriate for the patient to continue treatment
	5. Report adverse events of heart failure due to systolic dysfunction to Bristol Myers Squibb at 833-628-7367
	The CAMZYOS REMS will send reminders to the certified healthcare provider to submit the <i>Patient Status Form</i> . Completed forms should be submitted to the CAMZYOS REMS online at CAMZYOSREMS.com or via fax to 833-299-9539.
	Failure to submit the <i>Patient Status Form</i> at the required intervals could result in a delay in dispensing of CAMZYOS to the patient.

CAMZYOS® REMS Program Overview

Pharmacy Requirements

Only pharmacies certified in the CAMZYOS REMS can dispense CAMZYOS.

Become Certified	Before dispensing CAMZYOS:
	1. Designate an authorized representative to complete the certification process and oversee implementation and compliance with the REMS on behalf of the pharmacy
	2. Have the authorized representative review the following educational materials:
	Prescribing Information
	 Education Program for Healthcare Providers and Pharmacies
	Program Overview (this document)
	 Have the authorized representative successfully complete the <i>Pharmacy Authorized</i> <i>Representative Knowledge Assessment</i> and submit it to the REMS
	 Have the authorized representative enroll the pharmacy by completing the <i>Pharmacy</i> <i>Enrollment Form</i> and submitting it to the REMS
	5. Train all relevant staff involved in dispensing CAMZYOS using the <i>Program Overview</i> and the <i>Education Program for Healthcare Providers and Pharmacies</i>
	6. Establish processes and procedures to comply with the CAMZYOS REMS

CAMZYOS is not available to all pharmacies. If you have questions about the CAMZYOS REMS or how to obtain CAMZYOS, call 833-628-7367.

Program Overview

Pharmacy Requirements (continued)

Ensure Compliance	When dispensing CAMZYOS:		
With the CAMZYOS REMS Requirements	1. Counsel the patient on drug-drug interactions		
	 Assess the patient's prescription and nonprescription medications and supplements for drug-drug interactions. Document and submit to the REMS using the <i>Drug Interaction and</i> <i>Counseling Checklist for Pharmacies</i> 		
	3. Document the prescribed dose		
	4. Obtain authorization to dispense each prescription by contacting the REMS to verify that the:		
	 Prescriber is certified and the patient is enrolled 		
	 Healthcare provider has authorized the patient to receive the drug, the patient was counseled, and the pharmacy identified and resolved any drug-drug interactions 		
	5. Provide a Patient Brochure with each shipment of CAMZYOS		
	If needed, use the REMS website to submit an updated treatment start date within 90 days of the submission of the <i>Patient Enrollment Form</i>		
	 Dispense no more than a 35-day supply of CAMZYOS to patients in their first year of treatment. Dispense no more than a 90-day supply of CAMZYOS to patients beyond their first year of treatment 		
	 If the authorized representative of the pharmacy changes, have the new representative enroll in the REMS by successfully completing the <i>Pharmacy Authorized Representative</i> <i>Knowledge Assessment</i> and completing the <i>Pharmacy Enrollment Form</i> 		
	9. Report adverse events of heart failure due to systolic dysfunction to Bristol Myers Squibb at 833-628-7367		
	10. Do not distribute, transfer, loan, or sell CAMZYOS, except to a certified pharmacy		
	11. Maintain records of dispensing information		
	12. Maintain records documenting completion of the REMS training by relevant staff		
	13. Maintain records that all processes and procedures are in place and are being followed		
	14. Comply with audits conducted by Bristol Myers Squibb or a third party acting on behalf of Bristol Myers Squibb to ensure that all processes and procedures are in place and are being followed		

CAMZYOS is not available to all pharmacies. If you have questions about the CAMZYOS REMS or how to obtain CAMZYOS, call 833-628-7367.

CAMZYOS® REMS Program Overview

Patient Requirements

Only patients enrolled in the CAMZYOS REMS can receive CAMZYOS.

Become Enrolled	Before starting CAMZYOS:		
	 Receive counseling from the healthcare provider, using the <i>Patient Brochure</i>, on the: a. Risk of heart failure due to systolic dysfunction (when the heart is unable to pump enough blood to the body) b. Risk of drug-drug interactions and the need to inform healthcare providers of all prescription and over-the-counter medicines and supplements they take Get an echocardiogram to check their heart Enroll in the REMS by completing the <i>Patient Enrollment Form</i> with the healthcare provider. Enrollment information will be provided to the REMS Notify the healthcare provider if they delay taking their first dose of CAMZYOS more than 7 days after receiving their first prescription of CAMZYOS from the pharmacy 		
At All Times	After starting CAMZYOS:		
	 Receive counseling from the healthcare provider on the: a. Risk of heart failure due to systolic dysfunction b. Risk of drug-drug interactions and the need to inform healthcare providers of all prescription and over-the-counter medicines and supplements they take Get echocardiograms to check their heart Inform their healthcare providers or seek other medical attention if there are new or worsening symptoms of heart failure Inform their healthcare providers about their treatment with CAMZYOS Inform their healthcare providers of all concomitant products, including over-the-counter medicines and supplements. Patients must be advised not to take medicines contraindicated with CAMZYOS Review all prescription and over-the-counter medicines and supplements with their healthcare provider and pharmacist 		

Program Overview

Resources

The resources listed below are available for download at CAMZYOSREMS.com.

Healthcare Provider	Pharmacy	Patient
Prescribing Information	Prescribing Information	Medication Guide
Program Overview	Program Overview	Patient Brochure
 Education Program for Healthcare Providers and Pharmacies Healthcare Provider Knowledge Assessment Healthcare Provider Enrollment Form Patient Status Form Healthcare Provider Designee Enrollment Form 	 Education Program for Healthcare Providers and Pharmacies Pharmacy Authorized Representative Knowledge Assessment Pharmacy Enrollment Form Drug Interaction and Counseling Checklist for Pharmacies 	• Patient Enrollment Form

For more information about the CAMZYOS REMS, visit **CAMZYOSREMS.com** or call the CAMZYOS REMS at 833-628-7367.

Please see Important Safety Information, including **Boxed WARNING**, and US Full Prescribing Information for CAMZYOS <u>here</u>.